Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario-Reference-Cited by-同舟云学术

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

Published:2022-02-07 Issue:3 Volume:7 Page:379-385
ISSN:2058-5276
Container-title:Nature Microbiology
language:en
Short-container-title:Nat Microbiol

Author:

Nasreen Sharifa^ORCID,Chung Hannah,He Siyi,Brown Kevin A.,Gubbay Jonathan B.,Buchan Sarah A.,Fell Deshayne B.,Austin Peter C.,Schwartz Kevin L.,Sundaram Maria E.,Calzavara Andrew,Chen Branson^ORCID,Tadrous Mina,Wilson Kumanan,Wilson Sarah E.,Kwong Jeffrey C.^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology

Link

https://www.nature.com/articles/s41564-021-01053-0.pdf

Reference30 articles.

1. Weekly Epidemiological Update on COVID-19 2021 edn 43 (WHO, accessed 18 June 12021); https://apps.who.int/iris/bitstream/handle/10665/341716/CoV-weekly-sitrep8Jun21-eng.pdf.pdf?sequence=1

2. Weekly Epidemiological Update on COVID-19 2021 edn 59 (WHO, accessed 29 September 2021); https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19–28-september-2021

3. Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 397, 1351–1362 (2021).

4. Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 Variant. N. Engl. J. Med. 384, 1885–1898 (2021).

5. Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2110345 (2021).

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A potential antiviral against COVID-19 obtained from Byrsonima coccolobifolia leaves extract;Fitoterapia;2024-03

2. Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants;Current Microbiology;2024-02

3. Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice;Nature Communications;2024-01-26

4. Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population;Vaccines;2024-01-20

5. Perspectives and experiences of COVID-19 vaccination in people with autoimmune and inflammatory rheumatic disease;Patient Education and Counseling;2024-01